cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intellia Therapeutics Inc
125 own
45 watching
Current Price
$26.48
$0.06
(0.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,170.76M
52-Week High
52-Week High
43.06000
52-Week Low
52-Week Low
19.37000
Average Volume
Average Volume
1.17M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,170.76M
icon52-Week High43.06000
icon52-Week Low19.37000
iconAverage Volume1.17M
iconDividend Yield--
iconP/E Ratio--
What does the Intellia Therapeutics Inc do?
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Intellia Therapeutics Inc make?
News & Events about Intellia Therapeutics Inc.
PR Newswire
1 year ago
Thinking about buying stock in Advanced Health Intelligence, Intellia Therapeutics, Globant SA, BILL Holdings, or ONEOK? Thinking about buying stock in Advanced Health Intelligence, Intellia Therapeutics, Globant SA, BILL Holdings, or ONEOK? PR Newswire NEW YORK, June 12, 2023 NEW YORK, June 12...
Globe Newswire
1 year ago
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients (n=10), a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-upAll patients who achieved ...
TipRanks Financial Blog
1 year ago
Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV Research Report), Cardinal Health (CAH Research ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV Research Report), Cardinal Health...
Benzinga
1 year ago
Intellia Therapeutics, Inc.(NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002 first-in-human studies in the coming months. read more...
Fool.com Headlines
1 year ago
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NASDAQ: NTLA) and Rivian Automotive(NASDAQ: RIVN...
Frequently Asked Questions
Frequently Asked Questions
What is Intellia Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Intellia Therapeutics Inc shares?
plus_minus_icon
How can I buy Intellia Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Intellia Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intellia Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Intellia Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Intellia Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intellia Therapeutics Inc?
plus_minus_icon
What percentage is Intellia Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intellia Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$26.48
$0.06
(0.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$140.49
$-5.50 (-3.77 %)
SI-BONE INC
SI-BONE INC
$16.15
$0.18 (1.13 %)
IMMATICS NV
IMMATICS NV
$12.29
$-0.10 (-0.81 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$4.67
$0.07 (1.41 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$140.49
$-5.50 (-3.77 %)
SI-BONE INC
SI-BONE INC
$16.15
$0.18 (1.13 %)
IMMATICS NV
IMMATICS NV
$12.29
$-0.10 (-0.81 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$4.67
$0.07 (1.41 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00